Active	Status	Sponsor type	Region	Phase	Filter
4 Active 22 Inactive 26 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
aleglitazar (R1439) / Roche
CTR20130332: Efficacy study of ALEGLITAZAR combined with metformin in patients with type 2 diabetes	Suspended	3		China	1. Common Chinese name: Aleglitazar; 1. Common Chinese name: Placebo	F.Hoffmann-La Roche Ltd. / Shanghai Roche Pharmaceutical Co., Ltd.	Indications: Type 2 diabetes mellitus
CTR20140085: Efficacy study of ALEGLITAZAR combined with metformin in patients with type 2 diabetes	Suspended	3	240	China	1. Generic Chinese name: Aleglitazar tablets, 0.15mg; 1. Generic Chinese name: Aleglitazar placebo tablets	F.Hoffmann-La Roche Ltd. / Shanghai Roche Pharmaceutical Co., Ltd.	Indications: Type 2 diabetes mellitus
CTR20130320: Evaluate the efficacy, safety, and tolerability of Aleglitazar in type 2 diabetes.	Suspended	3	240	China	1. Common Chinese name: Aleglitazar; 1. Common Chinese name: Placebo	F.Hoffmann-La Roche Ltd. / Shanghai Roche Pharmaceutical Co., Ltd.	Indications: Type 2 diabetes mellitus
CTR20140137: Aleglitazar may reduce cardiovascular risk in patients with type 2 diabetes who have recently developed ACS.	Suspended	3	300	China	1. Common Chinese name: Aliglitazar; 1. Common Chinese name: Placebo tablets matched with Aliglitazar	F. Hoffmann - La Roche Ltd/ Shanghai Roche Pharmaceutical Co., Ltd.	Indications: Type 2 diabetic patients experiencing acute coronary syndrome.